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Introduction 
 
Natural killer (NK) cells play a multitude of roles 
in host innate and adaptive immunity [1]. They 
possess the unique ability to recognize and lyse 
tumor and pathogen infected cells without any 
prior stimulation. This is achieved via direct ly-
sis, and indirectly by antibody dependent cellu-
lar cytotoxicity. They also promote B and T cell 
differentiation and dendritic cell (DC) matura-
tion [1]. In vivo, NK cells have a limited life span 
and therefore must be continually replenished 
[2]. It is well known that NK cells are derived 
from CD34+ hematopoietic progenitor cells 
(HPCs) and that IL-15 is crucial for their devel-
opment and homeostasis [3-5]. Despite this our 
understanding of the molecular mechanisms 
controlling NK cell development remains rudi-
mentary. 
 
Mouse knockout models have proved to be a 
very useful tool for studying the molecular 
mechanisms controlling murine NK cell develop-
ment. Most of this research has focused primar-
ily on the later stages of development with only 
a few studies identifying transcription factors 
involved in NK cell commitment and early devel-
opment. Although murine models are an invalu-
able tool for studying NK cell development, 
there are key differences between mouse and 
human NK cells. Therefore, it is essential that 
further research is conducted to confirm these 
results in humans. 
 
A thorough understanding of how NK cells de-
velop is important as disruptions in this devel-
opmental process are implicated in NK cell ma-
lignancies. Furthermore, an understanding of 
NK cell developmental mechanisms may enable 
future therapeutic manipulation. This review will 
discuss the different stages of NK cell develop-
ment with an emphasis on the molecular 
mechanisms involved at each stage and disrup-
tions leading to malignancies. 
 
NK cell developmental stages in mice 
 
The major focus of NK cell developmental re-
search has used the murine system. Here NK 
cell development occurs primarily in the bone 
marrow (BM), although immature NK cells are 
also present in the liver and thymus suggesting 
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development may also occur at these sites [6]. 
Like other blood cells, NK cells develop from 
CD34+ HPCs that undergo a sequential develop-
mental process where they gradually become 
more lineage restricted and lose their ability to 
self-renew. The acquisition of the β chain of the 
IL-2/15 receptor (CD122) marks one of the ear-
liest steps in NK cell commitment [6]. These NK 
precursors (NKPs) lack expression of T cell as-
sociated proteins and are unable to differenti-
ate into B , T , myeloid and erythroid cells, but 
can be stimulated to form mature NK cells in 
vitro [7]. NKPs also lack several NK cell recep-
tors with the exception of NKG2D and 2B4, re-
ceptors normally involved in activation or inhibi-
tion of killing activity in mature NK cells [7, 8]. 
 
As NKPs mature they gradually acquire more of 
the receptors seen on mature NK cells. The de-
velopment of immature NK (iNK) cells is associ-
ated with acquisition of NK1.1 and CD94-NKG2 
[9]. These iNK cells then acquire Ly49 and DX5 
and undergo a major expansion phase [9]. As 
these cells mature further, their proliferation 
rate slows and an increased expression of CD43 
and the gaining cytotoxicity and IFN-γ production 
distinguishes mature NK (mNK) cells [6, 9]. 
 
NK cell developmental stages in humans 
 
For several years it was believed that human NK 
cell development occurred primarily in the bone 
marrow. However, attempts to characterize NK 
cell developmental stages within the bone mar-
row have not been successful. The search for an 
alternative site of development led to the identi-
fication of a unique population of CD34+ 
CD45RA+ HPCs in secondary lymphoid tissues 
(SLTs) that was able to give rise to NK cells, T 
cells and myeloid DCs [4, 6]. These cells are 
now accepted as the first stage in NK cell devel-
opment and are termed pro-NK cells (CD34+ 
CD45RA+ CD117- CD94- CD122-) [3, 4]. 
 
Pro-NK cells are not IL-15 responsive however, 
following in vitro culture with FMS-like tyrosine 
kinase 3 ligand (FLT3L), IL-3 and IL-7, at least a 
fraction are able to give rise to IL-15 responsive, 
stage 2 pre-NK cells [10, 11]. This transition is 
marked by the acquisition of CD122 (IL-
2/15Rβ) and c-Kit (a cytokine receptor also 
known as CD117) [11]. Following stimulation 
with IL-2 or IL-15, a proportion of stage 2 pre-NK 
cells are able to form cells that are committed 
to the NK cell lineage. These cells represent the 
third stage of NK cell development and are 
known as immature NK cells (iNK cells) [11]. 
 
Although iNK cells no longer express CD34 and 
are restricted to form mature NK cells, they 
themselves lack features of mature NK cells. In 
particular, iNK cells show an inability to produce 
interferon γ (IFN-γ) and lack cytotoxicity [11]. 
Furthermore, iNK cells show variable expression 
of CD56 and do not express CD94. 
 
Functional maturation begins at stage 4 of NK 
cell development. Transition to this stage is as-
sociated with expression of the NK receptor, 
CD94-NKG2A [11, 12]. Stage 4 NK cells have a 
CD56bright CD16- phenotype and are the major 
population of mature NK (mNK) cells seen in 
SLTs (~90%). However, they represent only 10% 
of NK cells seen in the circulation. Here they are 
believed to be the main producer of NK cell-
derived IFN-γ. Although blood CD56bright CD16- 
NK cells are fully functional, within SLTs not all 
CD56brightCD16- NK cells express intracellular 
the cytolytic proteins perforin and granzyme B or 
produce IFN-γ. Therefore, it is likely that func-
tional maturation occurs within this stage of 
development. 
 
The major population of NK cells seen in periph-
eral blood are CD56dim CD16+. There is consid-
erable controversy regarding their development. 
It has been proposed that these cells may repre-
sent stage 5 of human NK cell development and 
differentiate from stage 4 CD56bright CD16- NK 
cells [12, 13]. There are several lines of evi-
dence which support this hypothesis. For exam-
ple, CD56bright CD16- NK cells have longer te-
lomeres than CD56dim CD16+ NK cells, suggest-
ing that the latter may be more terminally differ-
entiated [14]. Furthermore, only some CD56bright 
CD16- NK cells are granular whilst all CD56dim 
CD16+ NK cells have a granular morphology, 
with the presence of granules conferring func-
tional aptitude and therefore reflecting maturity 
[12]. Finally, it has been demonstrated that 
upon IL-2 stimulation in vitro, stage 4 CD56bright 
CD16- NK cells undergo phenotypic and func-
tional changes to form cells similar to stage 5 
CD56dim CD16+ NK cells [15]. Alternatively, 
CD56bright CD16- and CD56dim CD16+ NK cells 
may represent two terminally differentiated, 
functionally mature subsets. In this case, 
CD56dim CD16+ NK cells may develop from 
unique precursors that are not yet identified or 
from a common CD56bright/CD56dim NK cell pro-
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genitor. This hypothesis is supported by the ob-
servation that both CD56bright CD16- and 
CD56dim CD16+ NK cells play important roles 
within the innate immune response. Here 
CD56bright CD16- NK cells are the major media-
tors of NK cell-derived cytotoxicity while 
CD56bright CD16- NK cells produce copious 
amounts of NK cell-derived IFN-γ and other in-
flammatory cytokines. The importance of both 
these functions suggests that they represent 
two terminally differentiated, functionally ma-
ture subsets [16]. 
 
Despite the evidence supporting a role for SLTs 
in the development of NK cells, this does not 
reject a contribution from the BM to generate 
mature CD56+ NK cells. One theory is that the 
initial stages of NK cell development occur in 
BM and, under the influence of stromal cell fac-
tors, CD34+ HPC differentiate to form CD34+ 
CD45RA+ pro-NK cells. These cells then travel to 
the lymph nodes and tonsils where, under the 
influence of IL-2, they further differentiate and 
eventually form CD56bright CD16- NK cells and 
then CD56dim CD16+ NK cells. This is summa-
rized in Figure 1.  
 
Alternatively, the presence of pre-NK cells and 
Figure 1. Proposed Natural Killer (NK) Cell developmental pathway in Humans. In the bone marrow, HPCs differenti-
ate to form pro-NK cells which are able to differentiate into dendritic cells (DC), T cells and NK cells. It is proposed 
that some of these then migrate to the lymph nodes and tonsils, where they undergo further differentiation, whilst 
others remain and mature in the bone marrow. As pro-NK cells differentiate they gradually lose their ability to self 
renew and become more restricted in lineage potential. Immature NK (iNK) cells are restricted to form mature NK 
(mNK) cells but are themselves not functional. iNK cells differentiate into CD56bright CD16- mNK cells in vitro; however 
the precursors of CD56dim CD16+ remain uncertain. Following maturation, both CD16+ and CD16- mNK cells migrate 
to the blood. Here they play important roles in the immune response with CD16+ mNK cells being the main mediators 
of cytotoxicity and ADCC, and showing modest secretion of cytokines; whilst CD16- mNK cells appear to have a more 
immunoregulatory role, producing copious amounts of interferon-γ (IFN-γ) and other cytokines, but showing limited 
cytotoxic capabilities and an inability to perform ADCC. 
NK cell development and malignancies  
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mNK cells within the BM contributes to the hy-
pothesis that the complete developmental proc-
ess may also occur at this site [17]. It remains 
unclear whether the mNK cells originate from 
BM or represent venous blood contamination. It 
is speculated that mNK cells developing at dif-
ferent sites may have specialized functions. 
 
Forming committed NK precursors 
 
Detailed knowledge regarding the signals re-
quired for commitment of HPCs to the NK cell 
lineage is lacking, but is likely mediated by cell 
to cell interactions within the microenvironment. 
This is evident by the enhanced number of 
NKPs seen when HSCs are cultured on relevant 
stromal cell lines compared to those cultured 
alone [18]. The molecular signals delivered by 
these cells are only just beginning to be eluci-
dated, but appear to involve release of several 
cytokines including FLT3L and Stem Cell Factor 
(SCF). In vitro, addition of FLT3L or SCF to 
CD34+ HPCs greatly increased the frequency of 
NK cell precursor development and IL-15Rα 
expression [19]. Furthermore, mice deficient in 
FLT3L show reduced numbers of NK cells, DCs 
and HPCs [20]. Interestingly, mice that lack c-
Kit, the receptor for SCF, do not have any NK 
cell deficiencies, suggesting that it is not essen-
tial for in vivo development of NK cells [21]. 
 
The Ax1/Gas6 signaling pathway has also been 
implicated in the commitment and differentia-
tion of NK cells [22]. Ax1 is a tyrosine receptor 
kinase that is expressed by some CD34+ HPCs. 
Its ligand, Gas6, is also expressed by these 
cells, suggesting that Ax1 binds Gas6 in an 
autocrine fashion [22]. Interruption of this path-
way greatly diminishes NK cell precursor fre-
quency in human CD34+ HPCs cultured with 
SCF by impeding phosphorylation of c-Kit [22].  
 
Using knockout models several transcriptional 
factors that appear to be involved in NK cell 
development have been identified and are sum-
marized in Table 1. While there are a number of 
transcription factors that influence maturation 
of NK cells, a transcription factor that is essen-
tial for the generation of NKPs has yet to be 
identified. This is likely a result of the redun-
Table 1. Transcription factors involved in NK cell development as determined by mouse knockout mod-
els 
Transcription Factor Phenotype of Knockout Mouse References 
Commitment     
Ets-1 Decrease in NK cell numbers 
Impaired NK cell mediated cytotoxicity and IFN-γ secretion 
[23] 
PU.1* Reduced production of NKPs and mNKs 
Altered expression of receptors involved in development 
Defective proliferation in response to cytokines 
[26] 
Maturation     
STAT5 Developmental block at the NKP-iNK stage resulting in diminished 
NK cell numbers 
[31-33] 
E4BP4 Decrease in iNK cell numbers 
Almost undetectable mNK cells 
Impaired NK cell mediated cytotoxicity 
[35] 
Id2 Decrease in mNK cell numbers [36] 
Functional Maturation     
MEF Decrease in NK cell numbers 
Impaired NK cell mediated cytotoxicity and IFN-γ secretion 
Defective perforin expression 
[39] 
T-bet Decrease in NK cell numbers 
NK cells appear immature 
Impaired NK cell mediated cytotoxicity and IFN-γ secretion 
[40] 
BLIMP1 Decrease in peripheral mNK cell numbers 
Decrease in Granzyme B expression 
[42] 
* PU.1-/- mice die embryonically, therefore the role of PU.1 in NK development was determined by transfer of PU.1-/- 
fetal liver hematopoietic stem cells to Rag1-/-γc-/- mice. NK: Natural Killer; NKP: NK progenitors; iNK: immature NK; 
mNK: mature NK; IFN-γ: interferon-γ; STAT: signal transducer and activator of transcription; MEF: myeloid ELF1 (E74-
like factor 1)-like factor 
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dancy seen amongst transcription family mem-
bers, making it hard to ascribe them to specific 
functions. One such family is the Ets family of 
transcription factors. Within this family two fac-
tors, Ets-1 and PU.1 have been demonstrated to 
affect NKP generation. 
 
As NKPs develop from common lymphoid pro-
genitor cells (CLPs), an increase in Ets-1 is seen 
[7]. This transcription factor is thought to be 
essential for NK cell development as mice defi-
cient in Ets-1 have severe defects in NK cell 
lineages, showing reduced NK cell numbers and 
impaired NK cell cytolytic activity and IFN-γ se-
cretion [23]. Ets-1 may influence NK cell com-
mitment by increasing expression of CD122 [7, 
24]. This increase in CD122 may lead to a fur-
ther increase in Ets-1 expression as IL-15 has 
recently been shown to regulate Ets-1 post-
transcriptionally via the MEK > ERK1/2 > MNK1 
> eIF4E pathway [25]. Interestingly, the few 
mNK cells that do develop in Ets-1 deficient 
mice express CD122 suggesting CD122 is not 
exclusively controlled by Ets-1 [23]. 
 
PU.1 is well known for the important role it plays 
in the development of multipotent lymphoid 
progenitors. Since PU.1 deficient mice die em-
bryonically, the effect of PU.1 on NK cells has 
been demonstrated by transfer of PU.1-/- fetal 
liver hematopoietic stem cells (FL-HSCs) to 
Rag1-/-γc-/- mice [26]. These mice display re-
duced generation of NKP and mNK cells, sug-
gesting that PU.1 plays a role in early NK cell 
differentiation [26]. Furthermore, PU.1-/- mNK 
cells have alterations in Ly49, IL-7Rα and c-Kit 
expression and have defective responses to IL-2 
and IL-12 [26]. Interestingly though, when PU.1 
expression is decreased, but not abolished, an 
increase in NK and T cell genes is seen in mye-
loid and B cells [27]. This suggests that PU.1 
may enforce myeloid and B cell gene expression 
after lineage commitment by suppressing ex-
pression of NK and T cell genes [27]. 
 
Maturation of Precursor NK cells 
 
Acquisition of the high-affinity β-chain of the IL-
15 receptor, CD122, is an essential step in the 
commitment of HPCs to the NK cell lineage in 
both humans and mice. Therefore, it is no sur-
prise that the ligand for this receptor, IL-15, 
would play a vital role in the maturation of NK 
cells. IL-15 is produced by accessory cells and 
presented to CD122 expressing NK cells in 
trans via the high-affinity IL-15Rα [28]. Mice 
that are genetically deficient in IL-15 or IL-15Rα 
lack NK cells [29]. Despite IL-15 being essential 
for development of mature NK cells, generation 
of NKPs from HPCs is IL-15 independent [8, 
29]. 
 
One way in which IL-15 influences NK cell matu-
ration is through the JAK3 > STAT5 signaling 
pathway. Binding of IL-15 or IL-2 to the IL-
2/15Rβγ chain results in phosphorylation of 
STAT5 by JAK3. STAT5 then dimerises and 
translocates to the nucleus where it serves as a 
transcription factor [30]. The essential role for 
STAT5 in NK cell development can be seen in 
mice deficient in STAT5a or b which show dimin-
ished NK cell numbers and combined deletion 
results in an absence of NK cells [31, 32]. NK-
specific deletion of STAT5 further confirmed this 
result, with deletion of STAT5 resulting in a de-
velopmental block at the NKP-iNK transition 
[33].  
 
Beyond the role for Ax1/Gas6 in the develop-
ment of NKPs, this pathway is also required for 
maturation of human NK cells. Interruption of 
the Ax1/Gas6 pathway results in fewer mature 
CD56bright NK cells with impaired IFN-γ produc-
tion [22]. Interestingly, blockade of the Ax1/
Gas6 pathway does not affect natural cytotoxic-
ity. This requirement is at least partially influ-
enced by interactions between the Ax1/Gas6 
pathway and the IL-15 signaling pathway, as 
impairment of the Ax1/Gas6 pathways impedes 
phosphorylation of STAT5 [22]. Similar results 
have also been demonstrated in mice, with 
knockout of Ax1 family members (Tryo3 and 
Mer) resulting in NK cells that were defective in 
both IFN-γ production and natural cytotoxicity 
[34]. 
 
The basic leucine zipper (bZIP) transcription 
factor, E4BP4, is essential for progression 
through the NKP-iNK and iNK-mNK transitions 
[35]. Mice lacking E4BP4 have considerably 
fewer iNK cells, almost no mNK cells and exhibit 
severely impaired NK cell-mediated cytotoxicity 
[35]. Importantly, they display normal numbers 
of NKPs, indicating that E4BP4 is not required 
for NK cell lineage specification. Like many NK 
cell transcription factors, E4BP4 expression 
appears to be IL-15 dependent [35]. One way in 
which E4BP4 may influence NK cell develop-
ment is by inducing expression of Id2 [35]. The 
Id proteins, specifically Id2 and Id3, are thought 
to function by inhibiting E protein activity and 
preventing B or T cell development and allowing 
NK cell development and malignancies  
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NK cell lymphopoiesis. Surprisingly, Id2 appears 
to be dispensable for the development of NKPs 
and iNK cells; however, it is essential for devel-
opment of mNK cells [36]. This requirement for 
Id2 is concomitant with a decrease in Id3 ex-
pression, suggesting that NKPs may develop in 
Id2 deficient mice because Id3 is sufficient to 
compensate for loss of Id2. Consistent with this 
hypothesis, Id2-/- mice showed increased ex-
pression of Id3 in CLPs and NKPs [36]. 
 
Functional maturation and homeostasis of mNK 
cells 
 
The development of functionally mature NK 
cells is associated with the expression of cyto-
toxic granules (namely perforin and granzyme B) 
and the ability to secrete IFN-γ. Concurrent with 
its important role in NK cell development, IL-15 
is also thought to influence functional matura-
tion by regulating perforin expression via the 
STAT5 pathway [37, 38]. Perforin expression 
has also been shown to be directly regulated by 
MEF, a member of the Ets family of transcription 
factors, with MEF-/- mice having reduced NK cell 
numbers with severally impaired perforin ex-
pression and cytotoxic ability. In addition, MEF-/- 
NK cells also show a reduced ability to secrete 
IFN-γ [39] 
 
The T-box family of transcription factors, specifi-
cally T-bet (Tbx21) and Eomesodermin (Eomes), 
have also been shown to influence NK cell func-
tional maturation. T-bet is thought to trigger 
functional maturation in NK cells by regulating 
perforin and granzyme B expression. Mice defi-
cient in T-bet show reduced numbers of NK cells 
which appear immature and have impaired 
function [40]. Interestingly combined deletion of 
T-bet and heterozygous deletion of Eomesoder-
min exacerbates this effect, with NK cell num-
bers being further diminished and expressing 
significantly less perforin [41]. One way in which 
T-bet may lead to functional maturation of NK 
cells is through the up-regulation of BLIMP1. It 
has recently been shown that T-bet-/- NK cells 
have significantly reduced expression of 
BLIMP1, an essential transcription factor for 
high granzyme B expression by NK cells. Inter-
estingly, BLIMP1 is not required for most cyto-
kine production and cytotoxicity but is required 
for NK cell homeostasis [42]. 
 
In addition to influencing development of NKPs, 
FLT3L is also important for mature NK cell ho-
meostasis in vivo. It has recently been shown 
that the effect of FLT3L on NK cells may be in-
fluenced, at least in part, by the tight link in DC 
and NK cell homeostasis. When mice were ad-
ministered recombinant FLT3L expansion of 
both CD11chi DCs and NK cells was observed. 
However, ablation of CD11chi DCs greatly re-
duced expansion of NK cells following FLT3L 
administration [43]. It is thought that FLT3L 
therapy induces expansion of IL-15 producing 
CD11chi DCs, this in turn expands NK cells [43]. 
 
MicroRNAs (miRNAs) have recently been shown 
to be indispensable for NK cell homeostasis. 
miRNAs are short (~22nt), non-coding RNA 
molecules that bind to target mRNAs and cause 
transcriptional repression or degradation. Dele-
tion of Dicer or DiGeorge syndrome critical re-
gion 8 (Dgcr8), two enzymes involved in miRNA 
biogenesis, results in a decrease in NK cells in 
the blood, spleen and liver as a result of de-
creased turnover rate and survival [44]. The 
remaining NK cells show defects in ITAM-
containing activating NK cell receptors and re-
tarded expansion during mouse cytomegalovi-
rus infection 
 
miRNAs also appear to be vital for NK cell acti-
vation. When human and mouse mNK cells are 
expanded and stimulated with IL-15 or IL-2 in 
vitro they show a dynamic change in their 
miRNA expression profiles [45, 46]. Of these 
miRNAs, miR223 shows a significant decrease 
in mouse NK cells following activation and has 
been shown to target murine granzyme B in 
vitro[45].  
 
NK cell malignancies 
 
NK cells are the cause of several aggressive 
lymphomas and leukemia. Although these dis-
eases are rare in western countries, they are 
relatively common in Asian populations [47, 
48]. The World Health Organization (WHO) di-
vides NK cell neoplasms into four main groups: 
Extranodal NK/T cell lymphoma, Nasal Type 
(ENKTL); Aggressive NK cell Leukemia/
Lymphoma; Chronic Lymphoproliferative Disor-
ders of NK cells (CLPD-NK), and NK cell lym-
phoblastic leukemia/lymphoma [49]. These are 
summarized in Table 2. The treatment of NK 
cell malignancies is beyond the scope of this 
review, for which readers are directed else-
where [48, 50, 51].  
 
The most common NK malignancy is ENKTL and 
therefore the majority of research is focused on 
NK cell development and malignancies  
 
40                                                                                                                                                                                                                     Am J Blood Res 2011;1(1):34-45 
 
Table 2. NK cell Malignancies 
 Natural killer (NK)-cell 
lymphoblastic leukemia / 
lymphoma 
 
Chronic lymphoproliferative 
disorders of NK-cells 
 
Aggressive NK-cell leukemia 
 
Extranodal NK/T-cell lymphoma, nasal 
type 
 
Definition  Provisional entity WHO 2008 
Leukemia due to NK-cell 
precursors  
 
Provisional entity WHO 2008 
Persistent (> 6 months) 
increase in peripheral blood 
NK cells (≥ 2.0 x 109/L) with 
no other identifiable cause  
Rare neoplastic proliferation of NK-
cells almost always associated with 
EBV causing an aggressive 
systemic disease 
 
Predominantly extranodal lymphoma 
causing vascular damage, destruction 
and prominent necrosis in association 
with EBV 
 
Presenting features 
 
Constitutional symptoms 
Leukemic blood picture 
Cytopenias  
Not associated with EBV 
infection 
Median age of onset 60 years 
No sex predominance 
No racial or genetic 
predisposition  
Presentation ranges from 
asymptomatic to systemic 
symptoms and cytopenias 
Lymphadenopathy and 
organomegaly rare 
Not associated with EBV 
infection 
More prevalent among Asian 
populations 
Median age of onset 42 years 
Slight male predominance 
Fever, constitutional symptoms, 
leukemic blood picture, cytopenias 
are common 
Hypersensitivity to mosquito bites, 
chronic active EBV infection 
More prevalent in Asians, native 
American populations of Mexico, 
Central and South America 
Median age of onset 50-60 years 
Male predominance 3:1 
Nasal and non-nasal mass lesions 
Disease activity can be monitored by 
measuring circulating EBV DNA 
Natural history Aggressive disease process Chronic indolent disease 
process 
Very aggressive disease process 
Median survival less than 2 months 
Aggressive disease process with 
variable prognosis 
Median survival 4-12 months 
Sites involved Peripheral blood and bone 
marrow 
Peripheral blood and bone 
marrow predominantly 
Peripheral blood, bone marrow, 
liver and spleen are commonest 
sites 
Skin involvement is uncommon 
  
Upper aerodigestive tract (nasal cavity, 
nasopharynx, paranasal sinuses, 
palate) commonly 
Other sites include skin, soft tissue, 
gastrointestinal tract and testis, rarely 
bone marrow 
Immunophenotype No specific markers  
May be CD2+, CD5+, CD7+, 
and cCD3ε+  
Diminished or lost CD2, CD7, 
and CD57 expression  
sCD3-, cCD3ε+, CD16+, CD56 
CD2+, sCD3-, cCD3ε+, CD56+ 
Cytotoxic molecules +  
Frequent CD16 and FAS ligand 
CD2+, sCD3-, cCD3ε+, CD56+ 
Cytotoxic molecules+ 
Negative: CD4, CD5, CD8, TCRδ, 
NK cell development and malignancies  
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T cell markers with CD16 
and CD56 expression in the 
absence of B-cell or myeloid 
markers 
CD94 or CD161 may be 
more specific but are not 
commonly tested 
 
 
weak 
Cytotoxic molecules* + 
Aberrant coexpression of CD5 
or uniform CD8 
Diminished CD161 
expression 
CD11b may be expressed 
CD57 usually negative  
EBER-ISH positive 
 
CD16, CD57 
Commonly positive: CD43, CD45RO, 
HLA-DR, CD25, FAS 
Occasionally positive: CD7, CD30 
EBER-ISH positive 
 
Morphology  PB: Intermediate to large 
monocytoid cells, immature 
nuclear features with high 
nuclear:cytoplasmic ratio 
 
PB: Intermediate sized 
lymphoid cells with round 
nuclei, condensed chromatin 
Moderate amounts of slightly 
basophilic cytoplasm 
containing fine or coarse 
azurophilic granules 
BM: Intrasinusoidal and 
interstitial infiltration of 
lymphoid cells with minimally 
irregular nuclei and modest 
amounts of pale cytoplasm  
 
PB: Ranges from the appearance of 
normal LGLs$ to lymphoid cells with 
atypical enlarged nuclei with 
irregular foldings, open chromatin 
or distinct nucleoli 
Ample amount of pale or lightly 
basophilic cytoplasm containing 
azurophilic granules 
BM: Range of disease infiltration of 
usually monotonous cells with 
intermingled reactive histiocytes 
and sometimes 
haemophagocytosis 
Associated apoptotic bodies and 
necrosis is common  
Soft tissue: Angiocentric or 
angiodestructive growth pattern with 
fibrinoid changes in blood vessels, 
there may be associated inflammatory 
infiltrate 
Broad cytological spectrum with 
variation in size, irregularly folded and 
sometimes elongated nuclei, granular 
chromatin, inconspicuous or small 
nucleoli 
Moderate amount of pale or clear 
cytoplasm 
 
Current treatment 
strategies  
Intensive combination 
chemotherapy  
Monitor for progression / 
transformation 
Combination chemotherapy 
including L-asparaginase e.g. 
SMILE# 
Consider allogeneic hematopoietic 
stem cell transplantation (HSCT) 
 
Chemoradiotherapy or radiotherapy 
alone for localized disease  
Combination chemotherapy including 
L-Asparaginase e.g. SMILE for 
disseminated disease 
Consider high-dose chemotherapy and 
autologous or allogeneic (HSCT)  
PB: peripheral blood, BM: bone marrow; * Cytotoxic molecules include TIA-1, granzyme B, granzyme M, perforin; $ Large granular lymphocytes; # SMILE 
chemotherapy: dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide. Information in table from [47, 49, 51, 61-64] 
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this disease. ENKTL is characterized by a dif-
fuse proliferation of mature NK cells and is gen-
erally localized to the nasal cavity, although dis-
ease can occur at other sites [48, 52]. The 
mechanisms underlying ENKTL development 
are poorly understood, however its strong asso-
ciation with the Epstein-Barr virus (EBV) sug-
gests the virus may have an etiological role [48, 
52]. EBV is a gamma-herpes virus with known 
oncogenic properties that is implicated in a 
range of B, T and NK cell lymphoid malignancies 
[53]. Although its principal reservoir is B cells, 
large expansions of circulating EBV infected NK 
cells are apparent in EBV associated hemo-
phagocytic syndrome and chronic active EBV 
syndrome [54]. 
 
Patients with ENKTL show elevated serum lev-
els of IL-15 compared to healthy controls [55]. 
This increase in IL-15 allows ENKTL tumor sur-
vival, likely through phosphorylation of AKT, a 
serine/threonine kinase with anti-apoptotic ac-
tivity [55]. In addition, over expression of IL-15 
in mice causes development of fatal lympho-
cytic leukemia with a T/NK phenotype [56]. It 
has also been suggested that over-expression of 
T-bet may be a transforming event in the devel-
opment of ENKTL. ENKTL cells show amplifica-
tion and over-expression of T-bet which may 
have lead to tumorgenesis through loss of 
growth control and over-function [57] . Several 
other transcription factors associated with NK 
cell development including Eomes, MEF and 
Ets1 have also been recently shown to be ex-
pressed in ENKTL [7, 39, 58].  
 
Similar to ENKTL, Aggressive NK cell Leukemia/
Lymphoma is also believed to be triggered by 
infection of NK cells with the EBV [48]. As ag-
gressive NK cell Leukemia/Lymphoma is such a 
rare disease, our understanding of it is limited. 
Based on the expression of CD56 and CD94 
and the lack of CD3, this disease appears to 
have a mature NK cell origin [59]. However, 
morphologically, malignant cells appear imma-
ture with a fine chromatin pattern and large, 
pale cytoplasm [48, 50]. As such, it is proposed 
that transformation may occur at an early stage 
of development, possibly during transition from 
stage 3 to stage 4, and trigger up regulation of 
these surface receptors. 
 
CLPD-NK is a rare entity that is characterized by 
expansion of mature looking NK cells in the pe-
ripheral blood. Based on the expression of 
CD16 and low levels of CD56, this disease ap-
pears to have a stage 5 mature NK cell origin 
[48, 50]. CLPD-NK is speculated to develop in 
response to a stimulus, likely of viral origin, acti-
vating mNK cells and selecting for clones [50]. 
The origin of this stimulus, however, remains 
undefined but is likely to reside in the bone mar-
row where it is presented to mNK cells by in-
fected DCs [50]. 
 
Unlike the other NK cell malignancies, NK cell 
Lymphoblastic Leukemia/Lymphoma appears to 
have an immature NK cell origin. Neoplastic 
cells express CD56 but have a blastic appear-
ance, suggesting they likely arise from stage 3 
iNK cells [48, 60]. Likely as a result of its rarity, 
little is known about what causes NK cell Lym-
phoblastic Leukemia/Lymphoma. As with CLPD-
NK, EBV is not expressed within the malignant 
NK cell. 
 
Concluding Remarks 
 
An understanding of normal human NK cells 
development will enable the pathogenesis of NK 
cell malignancies to be elucidated. Perturba-
tions in cytokines, transcription factors, miRNAs 
and transcription factors are all likely to be im-
plicated, as well as the transforming role of EBV. 
However, the majority of research remains in 
the mouse. Future research into pathogenesis 
is needed, that specifically integrates observa-
tions from patient material with in vivo and in 
vitro models of human NK cell development. 
Insights into how disruptions in normal NK cell 
developmental pathways contribute to tumorge-
nesis are critical for the development of new 
targeted therapies. 
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